Pre-clinical Pharmacology of Moclobemide: A Review of Published Studies

The novel antidepressant, moclobemide, is a reversible inhibitor of monoamine oxidase (MAO) preferentially of monoamine oxidise-A (MAO-A); it emerged for study out of a series of lipid-lowering agents. In spite of its weak MAO-A inhibition in vitro , moclobemide is a potent inhibitor of MAO-A, in vi...

Full description

Saved in:
Bibliographic Details
Published in:British journal of psychiatry 1989-10, Vol.155 (S6), p.84-88
Main Authors: Haefely, Willy, da Prada, Mosé, Kettler, Rolf, Keller, Hans H., Burkard, Willy P.
Format: Article
Language:English
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The novel antidepressant, moclobemide, is a reversible inhibitor of monoamine oxidase (MAO) preferentially of monoamine oxidise-A (MAO-A); it emerged for study out of a series of lipid-lowering agents. In spite of its weak MAO-A inhibition in vitro , moclobemide is a potent inhibitor of MAO-A, in vivo ; its in vivo activity is of short duration, in contrast to the extremely long-lasting inhibition, e.g. by tranylcypromine. Moclobemide only slightly potentiates the pressor effect of oral tyramine in freely moving rats, again in contrast to tranylcypromine; it is not anti-cholinergic and is free of hepatotoxicity. Published evidence on the preclinical pharmacology is reviewed.
ISSN:0007-1250
1472-1465
DOI:10.1192/S0007125000297547